Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)

About this Study

A Phase III clinical trial designed to test the efficacy and safety of anticoagulation,compared with aspirin, in patients with a recent intracerebral hemorrhage (ICH) and high-risk non-valvular atrial fibrillation/flutter (AF).

Sponsor Protocol ID:NCT03907046
IRB Number:2019-0338
Actively Enrolling
Interventional
Phase 3
January 27, 2020
Eligibility Criteria
18 years old
Both Male and Female
No
No
No

Inclusion Criteria Age at least 18 years
 Provision of signed and dated informed consent form by patient or legally authorized representative 
 Expected to comply with all study procedures and be available for duration of the study 
 For females of reproductive potential: use of highly effective contraception 

Exclusion Criteria
 Pregnant or breastfeeding 
 Known allergy to aspirin or apixaban 
 Concomitant participation in a competing therapeutic trial 
 Considered by the investigator to have a condition that precludes safe participation in the trial 

Categories Click category to view its trials.
Stroke/Traumatic Brain Injury
Participating Locations
Pavilion - University Physicians
University Hospital
Contact Information
Contact Name: Sandra Powe
Phone Number: 601-815-5288
Email: spowe@umc.edu
Principal Investigator:Washington, Chad W, M.D.
How to participate in our Clinical Trials